The FDA accepts Merck's (MRK -0.5%) NDA for the investigational anti-thrombotic medicine,...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

The FDA accepts Merck's (MRK -0.5%) NDA for the investigational anti-thrombotic medicine, vorapaxar for "the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack." The drug has faced an uphill battle since being acquired by MRK in 2009 and, according to Reuters, some analysts question whether bleeding risk will limit its adoption if approved.